MF-2
Internal request:
Provide some guidance on the use of ruxolitinib or another JAK2 inhibitor prior to allogeneic stem cell transplantation in patients with myelofibrosis (MF).

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
|                            | The panel consensus was to include the following footnote for transplant candidates with higher risk MF: Ruxolitinib or fedratinib may be continued near to the start of conditioning therapy for the improvement of splenomegaly and other disease-related symptoms. References:  